Judith C. Lunger
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Judith C. Lunger has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
- Antonio Salcido-Alcántar
Department of Genetics, Stanford University School of Medicine, Stanford, CA 94305, USA
4 shared publications - Jenny Y. Liu
Department of Genetics, Stanford University School of Medicine, Stanford, CA 94305, USA
4 shared publications - Lucas E. Sant’ANna
Department of Genetics, Stanford University School of Medicine, Stanford, CA 94305, USA
4 shared publications - Wansang Cho
Department of Genetics, Stanford University School of Medicine, Stanford, CA 94305, USA
4 shared publications Alex N. Beckett
3 shared publications- Elena Sotillo
Stanford University
2 shared publications
Latest Publications
- Open Access
- 14 July 2026
- Published by Elsevier in SSRN Electronic Journal
Programmable Signaling Drives CAR T Cells to Enhanced Functional States
Cytokine receptors have evolved to use a limited set of conserved signaling motifs to encode remarkably diverse cellular responses. Using 12 signaling motifs, we created Programmable Activators of Cell Signaling (PACS) that activate complex non-natural signaling programs unconstrained by the evolved architecture of natural cytokine receptors. We experimentally tested 457 unique PACS in chimeric antigen receptor (CAR) T cells and trained models to identify PACS features that promote memory, cytotoxicity, and autonomous proliferation. Recombination of signaling motifs created a broad spectrum of signaling and corresponding CAR T cell phenotype. PACS signaling domains serve as a configurable programming layer whose motifs systematically alter STAT phosphorylation to encode cell phenotype. Guided by machine learning models, we rationally designed two PACS with tuned signaling profiles that increase CAR T cell memory and cytotoxicity while reducing toxicity. This work provides a platform for multi-parameter optimization of therapeutic cell functions to improve efficacy and safety.
- 14 July 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessProgrammable Signaling Drives CAR T Cells to Enhanced Functional States
Cytokine receptors have evolved to use a limited set of conserved signaling motifs to encode remarkably diverse cellular responses. Using 12 signaling motifs, we created Programmable Activators of Cell Signaling (PACS) that activate complex non-natural signaling programs unconstrained by the evolved architecture of natural cytokine receptors. We experimentally tested 457 unique PACS in chimeric antigen receptor (CAR) T cells and trained models to identify PACS features that promote memory, cytotoxicity, and autonomous proliferation. Recombination of signaling motifs created a broad spectrum of signaling and corresponding CAR T cell phenotype. PACS signaling domains serve as a configurable programming layer whose motifs systematically alter STAT phosphorylation to encode cell phenotype. Guided by machine learning models, we rationally designed two PACS with tuned signaling profiles that increase CAR T cell memory and cytotoxicity while reducing toxicity. This work provides a platform for multi-parameter optimization of therapeutic cell functions to improve efficacy and safety.
- Open Access
- 11 July 2026
- Published by Elsevier in SSRN Electronic Journal
Programmable Activators of Cell Signaling Polarize Macrophages to User-Defined Functional States
Technology that precisely controls macrophage polarization would deepen our understanding of macrophage biology and enable new macrophage-based cell therapies. Here, we use Programmable Activators of Cell Signaling (PACS), a synthetic receptor platform with modular signaling motifs, to control primary human macrophage polarization. Random recombination of nine distinct signaling motifs generates diverse synthetic macrophage states with varied expression of surface markers and E. coli phagocytosis capacity. PACS programmed with multiple YLxQ motifs increase chimeric antigen receptor (CAR)-macrophage phagocytosis of cancer cells in mice, reducing tumor burden 30-fold. A two-state model describes the motif-dependent polarization well, enabling prediction of macrophage state from PACS signaling domain composition. We apply this model to rationally design a PACS receptor that enables macrophages to adopt a highly phagocytic phenotype while retaining pro-inflammatory activity. Together, these findings establish a framework for synthetic programming of macrophage polarization states, with potential applications in cancer immunotherapy and other disease contexts.
- 11 July 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessProgrammable Activators of Cell Signaling Polarize Macrophages to User-Defined Functional States
Technology that precisely controls macrophage polarization would deepen our understanding of macrophage biology and enable new macrophage-based cell therapies. Here, we use Programmable Activators of Cell Signaling (PACS), a synthetic receptor platform with modular signaling motifs, to control primary human macrophage polarization. Random recombination of nine distinct signaling motifs generates diverse synthetic macrophage states with varied expression of surface markers and E. coli phagocytosis capacity. PACS programmed with multiple YLxQ motifs increase chimeric antigen receptor (CAR)-macrophage phagocytosis of cancer cells in mice, reducing tumor burden 30-fold. A two-state model describes the motif-dependent polarization well, enabling prediction of macrophage state from PACS signaling domain composition. We apply this model to rationally design a PACS receptor that enables macrophages to adopt a highly phagocytic phenotype while retaining pro-inflammatory activity. Together, these findings establish a framework for synthetic programming of macrophage polarization states, with potential applications in cancer immunotherapy and other disease contexts.
- Open Access
Programmable synthetic cytokine receptors polarize macrophages to user-defined functional states
Summary: Technology that precisely controls macrophage polarization to distinct functional states would deepen our understanding of macrophage biology and enable the development of new macrophage cell therapies. Here, we use a synthetic cytokine receptor (SCR) platform with a programmable signaling domain to control the polarization of primary human macrophages. SCRs containing signaling motifs from the interferon-gamma (IFN-γ) or Interleukin-10 (IL-10) receptors mimic key features of pro-inflammatory or anti-inflammatory polarization, respectively. Random recombination of nine distinct signaling motifs to create new SCR signaling domains generates a diverse landscape of synthetic macrophage states with varied expression of inflammatory markers (CD80, CD40) and anti-inflammatory markers (CD163, CD206), and varied phagocytic capacity. SCRs programmed with multiple YLxQ motifs increase macrophage phagocytosis of E. coli and chimeric antigen receptor (CAR)-macrophage phagocytosis of cancer cells in mice, reducing tumor burden by 30-fold. The motif-dependent polarization is well-described by a two-state model, enabling quantitative prediction of macrophage polarization state from SCR signaling domain composition. Leveraging this model, we design an SCR that simultaneously enhances phagocytosis and maintains a macrophage pro-inflammatory state. Together, these findings establish a framework for synthetic programming of macrophage polarization states, with potential applications in cancer immunotherapy and other disease contexts.
Open AccessProgrammable synthetic cytokine receptors polarize macrophages to user-defined functional states
Summary: Technology that precisely controls macrophage polarization to distinct functional states would deepen our understanding of macrophage biology and enable the development of new macrophage cell therapies. Here, we use a synthetic cytokine receptor (SCR) platform with a programmable signaling domain to control the polarization of primary human macrophages. SCRs containing signaling motifs from the interferon-gamma (IFN-γ) or Interleukin-10 (IL-10) receptors mimic key features of pro-inflammatory or anti-inflammatory polarization, respectively. Random recombination of nine distinct signaling motifs to create new SCR signaling domains generates a diverse landscape of synthetic macrophage states with varied expression of inflammatory markers (CD80, CD40) and anti-inflammatory markers (CD163, CD206), and varied phagocytic capacity. SCRs programmed with multiple YLxQ motifs increase macrophage phagocytosis of E. coli and chimeric antigen receptor (CAR)-macrophage phagocytosis of cancer cells in mice, reducing tumor burden by 30-fold. The motif-dependent polarization is well-described by a two-state model, enabling quantitative prediction of macrophage polarization state from SCR signaling domain composition. Leveraging this model, we design an SCR that simultaneously enhances phagocytosis and maintains a macrophage pro-inflammatory state. Together, these findings establish a framework for synthetic programming of macrophage polarization states, with potential applications in cancer immunotherapy and other disease contexts.
- Open Access
A continuous landscape of signaling encodes a corresponding landscape of CAR T cell phenotype
Cytokine signaling is critical to the function of natural immune cells and engineered immune cell therapies such as chimeric antigen receptor (CAR) T cells. It remains unclear how the limited set of signal transducers and activators of transcription (STATs) and other proteins activated by these cytokine receptors can encode the observed diversity of immune cell phenotypes. To understand how signaling downstream of cytokines control immune cell phenotype, we sought to map the structure of Janus kinase (JAK)/STAT signaling domains to cell signaling and resulting CAR T cell function. We recombined 14 signaling motifs to construct a library of ∼30,000 constitutively active synthetic cytokine receptors (SCRs) with intracellular domains composed of novel signaling motif combinations that activate different signaling cascades. We experimentally tested ∼450 SCRs which generated a range of CAR T cell memory, cytotoxicity, and proliferation. SCRs with pSTAT1 and 3 signaling generated effector memory CAR T cells, while SCRs with strong pSTAT5 generated effector CAR T cells with potent anti-tumor activity. To map the structure-signaling-phenotype landscape we trained models to predict signaling and CAR T cell phenotype that result from varied motif combinations. From neural network predictions we identified features, including strong STAT5 and Shc signaling, that promote unsafe autonomous CAR T cell proliferation. Models also revealed a trade-off between memory and cytotoxicity, with a Pareto front encoded by a continuous change in signaling. These results demonstrate that recombination of a limited set of signaling motifs creates a continuous spectrum of signaling that encodes a corresponding spectrum of cell phenotype. This work synthetically expands the combinatorial space of JAK/STAT signaling and provides a foundation for rational design of CAR T cells with improved cytotoxicity, memory, and safety profiles. Abstract Figure:
Open AccessA continuous landscape of signaling encodes a corresponding landscape of CAR T cell phenotype
Cytokine signaling is critical to the function of natural immune cells and engineered immune cell therapies such as chimeric antigen receptor (CAR) T cells. It remains unclear how the limited set of signal transducers and activators of transcription (STATs) and other proteins activated by these cytokine receptors can encode the observed diversity of immune cell phenotypes. To understand how signaling downstream of cytokines control immune cell phenotype, we sought to map the structure of Janus kinase (JAK)/STAT signaling domains to cell signaling and resulting CAR T cell function. We recombined 14 signaling motifs to construct a library of ∼30,000 constitutively active synthetic cytokine receptors (SCRs) with intracellular domains composed of novel signaling motif combinations that activate different signaling cascades. We experimentally tested ∼450 SCRs which generated a range of CAR T cell memory, cytotoxicity, and proliferation. SCRs with pSTAT1 and 3 signaling generated effector memory CAR T cells, while SCRs with strong pSTAT5 generated effector CAR T cells with potent anti-tumor activity. To map the structure-signaling-phenotype landscape we trained models to predict signaling and CAR T cell phenotype that result from varied motif combinations. From neural network predictions we identified features, including strong STAT5 and Shc signaling, that promote unsafe autonomous CAR T cell proliferation. Models also revealed a trade-off between memory and cytotoxicity, with a Pareto front encoded by a continuous change in signaling. These results demonstrate that recombination of a limited set of signaling motifs creates a continuous spectrum of signaling that encodes a corresponding spectrum of cell phenotype. This work synthetically expands the combinatorial space of JAK/STAT signaling and provides a foundation for rational design of CAR T cells with improved cytotoxicity, memory, and safety profiles. Abstract Figure:
- Open Access
- 9 January 2024
- Published by Oxford University Press (OUP) in NAR Cancer
- Vol. 6 (1) , zcae004
Rewiring of RNA methylation by the oncometabolite fumarate in renal cell carcinoma
Metabolic reprogramming is a hallmark of cancer that facilitates changes in many adaptive biological processes. Mutations in the tricarboxylic acid cycle enzyme fumarate hydratase (FH) lead to fumarate accumulation and cause hereditary leiomyomatosis and renal cell cancer (HLRCC). HLRCC is a rare, inherited disease characterized by the development of non-cancerous smooth muscle tumors of the uterus and skin, and an increased risk of an aggressive form of kidney cancer. Fumarate has been shown to inhibit 2-oxoglutarate-dependent dioxygenases (2OGDDs) involved in the hydroxylation of HIF1α, as well as in DNA and histone demethylation. However, the link between fumarate accumulation and changes in RNA post-transcriptional modifications has not been defined. Here, we determine the consequences of fumarate accumulation on the activity of different members of the 2OGDD family targeting RNA modifications. By evaluating multiple RNA modifications in patient-derived HLRCC cell lines, we show that mutation of FH selectively affects the levels of N6-methyladenosine (m6A), while the levels of 5-formylcytosine (f5C) in mitochondrial tRNA are unaffected. This supports the hypothesis of a differential impact of fumarate accumulation on distinct RNA demethylases. The observation that metabolites modulate specific subsets of RNA-modifying enzymes offers new insights into the intersection between metabolism and the epitranscriptome.
- 9 January 2024
- Published by Oxford University Press (OUP) in NAR Cancer
- Vol. 6 (1) , zcae004
Open AccessRewiring of RNA methylation by the oncometabolite fumarate in renal cell carcinoma
Metabolic reprogramming is a hallmark of cancer that facilitates changes in many adaptive biological processes. Mutations in the tricarboxylic acid cycle enzyme fumarate hydratase (FH) lead to fumarate accumulation and cause hereditary leiomyomatosis and renal cell cancer (HLRCC). HLRCC is a rare, inherited disease characterized by the development of non-cancerous smooth muscle tumors of the uterus and skin, and an increased risk of an aggressive form of kidney cancer. Fumarate has been shown to inhibit 2-oxoglutarate-dependent dioxygenases (2OGDDs) involved in the hydroxylation of HIF1α, as well as in DNA and histone demethylation. However, the link between fumarate accumulation and changes in RNA post-transcriptional modifications has not been defined. Here, we determine the consequences of fumarate accumulation on the activity of different members of the 2OGDD family targeting RNA modifications. By evaluating multiple RNA modifications in patient-derived HLRCC cell lines, we show that mutation of FH selectively affects the levels of N6-methyladenosine (m6A), while the levels of 5-formylcytosine (f5C) in mitochondrial tRNA are unaffected. This supports the hypothesis of a differential impact of fumarate accumulation on distinct RNA demethylases. The observation that metabolites modulate specific subsets of RNA-modifying enzymes offers new insights into the intersection between metabolism and the epitranscriptome.
- Open Access
- 15 June 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (12_Supplem) , 4108
Abstract 4108: Understanding the role of telomere biology gene variation in cancer etiology
Telomere biology disorders (TBDs) are cancer-prone syndromes associated with increased risk of acute myeloid leukemia (AML), head and neck squamous cell carcinoma (HNSCC), bone marrow failure, pulmonary fibrosis, and liver disease. Germline variants in at least 15 different telomere biology genes have been implicated (ACD, CTC1, TERT, TERC, STN1, NAF1, NOP10, NHP2, TINF2, RTEL1, PARN, ZCCHC8, DKC1, WRAP53, POT1) with autosomal dominant (AD), autosomal recessive (AR), or X-linked (XLR) inheritance as well as de novo occurrence. We hypothesize that TBDs may be more common than the currently estimated 1:1,000,000. We analyzed the prevalence of germline variants in the 15 TBD-associated genes using 1) The Genome Aggregation Database [gnomAD v2.1.1 non-cancer] and 2) The Cancer Genome Atlas (TCGA). Germline TCGA variants were called using HaplotypeCaller, Freebayes, and UnifiedGenotyper. All variants with minor allele frequency (MAF) Citation Format: Marena R. Niewisch, Jung Kim, Judith C. Lunger, Lisa J. McReynolds, Sharon A. Savage. Understanding the role of telomere biology gene variation in cancer etiology [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 4108.
- 15 June 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (12_Supplem) , 4108
Open AccessAbstract 4108: Understanding the role of telomere biology gene variation in cancer etiology
Telomere biology disorders (TBDs) are cancer-prone syndromes associated with increased risk of acute myeloid leukemia (AML), head and neck squamous cell carcinoma (HNSCC), bone marrow failure, pulmonary fibrosis, and liver disease. Germline variants in at least 15 different telomere biology genes have been implicated (ACD, CTC1, TERT, TERC, STN1, NAF1, NOP10, NHP2, TINF2, RTEL1, PARN, ZCCHC8, DKC1, WRAP53, POT1) with autosomal dominant (AD), autosomal recessive (AR), or X-linked (XLR) inheritance as well as de novo occurrence. We hypothesize that TBDs may be more common than the currently estimated 1:1,000,000. We analyzed the prevalence of germline variants in the 15 TBD-associated genes using 1) The Genome Aggregation Database [gnomAD v2.1.1 non-cancer] and 2) The Cancer Genome Atlas (TCGA). Germline TCGA variants were called using HaplotypeCaller, Freebayes, and UnifiedGenotyper. All variants with minor allele frequency (MAF) Citation Format: Marena R. Niewisch, Jung Kim, Judith C. Lunger, Lisa J. McReynolds, Sharon A. Savage. Understanding the role of telomere biology gene variation in cancer etiology [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 4108.